Semax: A Russian Drug, Unapproved Here

What is Semax, and where is it a drug?

Semax is a synthetic heptapeptide built from the ACTH(4–7) fragment of adrenocorticotropic hormone with a proline-glycine-proline tail added for stability, developed in Moscow and given there as a nasal spray. Its standing as a medicine is a Russian fact as far as its own literature records it: a 2000 ophthalmology report describes it in its own title as a new Russian drug ^[9], and the clinical literature that follows lives in that country's journals; no registration record was read for this review, and none is claimed.

The mechanistic case for a nootropic effect is real and is where the marketing starts. In rat hippocampus the peptide raises brain-derived neurotrophic factor and trkB receptor expression ^[1], and it binds brain tissue with measurable specificity ^[2]. A receptor finding in a rat is the beginning of a claim, not its proof, and the monograph records the regulatory position with the date it was verified. What has been done in people, and where, is counted below.

How many human trials exist, and in what language?

Four, and all four are Russian-language. Searched in September 2026 across three names, PubMed returns 216 indexed records, 49 tagged Humans, 4 under the clinical-trial publication type and 1 under the randomized type ^[6]. The language split is the finding: 93 of the records are Russian-language and 125 English-language, yet the trial filters combined with English[Language] return 0 under either type, while combined with Russian[Language] they return all 4 ^[6]. Only 22 English-language records carry the Humans heading at all ^[6].

The filters were proved live against a control term in the same session, and the reference records the counts ^[6]. Adding the terms nootropic or cognit* to the clinical-trial filter returns the same four records, so there is no separate cognition file hiding behind a different vocabulary ^[6].

What do the four trials report?

A 1997 study gave the peptide to 30 patients in the acute period of hemispheric ischemic stroke and compared them with 80 patients on conventional therapy, reporting faster regression of motor deficits at daily doses of 12 mg and 18 mg ^[7]. A 2000 study in optic-nerve disease divided patients into three groups by route of administration, nasal drops, endonasal electrophoresis and control, and reported improved visual acuity and visual field; its abstract gives no patient count ^[9].

A 2007 study treated 27 patients with motor neuron disease in an open-label design in sequential groups and found that the peptide did not influence the course of denervation or the clinical scores, while reporting an improvement in a quality-of-life total driven by emotional state and motivation ^[8]; PubMed tags that record as the one randomized trial in the file, and its own abstract calls it open-label. A 2018 study followed 110 patients after ischemic stroke, divided by rehabilitation timing and by whether they received the peptide, and reported higher plasma BDNF and better Barthel scores in the treated subgroups ^[3].

That is the whole controlled file: stroke, optic nerve, motor neuron disease. Not one enrolls healthy adults, not one measures memory, attention or any cognitive-enhancement endpoint in a person without a neurological diagnosis, and not one has been published outside that country's journals, let alone reviewed by a regulator outside Russia. The nootropic claim is an inference drawn across that gap, and the trial record prints the four records beside every other count in the index.

What does the Russian registration mean in the United States?

As a matter of marketing status, nothing. A drug approved by another country's regulator holds no United States approval, and the mechanism that confers one, an application reviewed by FDA, has not been used: Drugs@FDA returns no application under the name, while the identical query returned NDA 210557 for a control term in the same run ^[12]. The substance appears in no category of the section 503A bulks list published on May 14, 2026 ^[11].

FDA's own statement on the compound, still published among substances nominated but withdrawn, is that it has no, or limited, safety-related information for the proposed routes of administration and therefore lacks sufficient information to know whether the drug would cause harm if administered to humans ^[10]. That sentence sits beside a Russian dossier the agency has never examined; the two are not in conflict, because one is a record of what FDA has reviewed and the other is a record of what another country has.

In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding Semax to the section 503A list, on a margin reported as 8–5 with one abstention by McDermott Will & Schulte and by LumaLex Law, whose separate accounts agree substance by substance ^{[4, 5]}; the FDA has published no minutes, transcript or vote summary, so the figure is secondary wherever it is printed. The vote is advisory. The vote ledger carries the arithmetic for all seven substances, and the pending page explains what an advisory recommendation changes, which is nothing until a final rule issues.

What is sold, and under what posture?

Nasal sprays and vials offered to United States buyers are research-use-only supply or gray-market imports, outside pharmacy licensure and prescriber oversight; the research-use-only entry sets out what that labeling posture does and does not mean. A reader who buys on the strength of the Russian registration is buying a product that registration does not cover, made by a manufacturer that registration does not govern.

The nearest comparison in this index is the molecule that shared its meeting. DSIP is filed in the same neuropeptides class and is the one peptide the same panel is reported, by the same two accounts, to have voted against, on a record older and thinner than this one ^{[4, 5]}; the DSIP review reads that outcome. Semax cleared the panel on a Russian clinical file and a rat mechanism, and neither has been examined by a regulator in the place where the product is being sold.

Elsewhere in this index